Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TAK-228 as a single agent in adult East Asian participants with advanced nonhematological malignancies was terminated; results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonhematological Neoplasms

Drugs mentioned

• TAK-228

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Advanced Nonhematological Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2020-09-09